These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38321556)

  • 1. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
    Kikuchi K; Ogawa M; Sasaki A
    J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.
    Ochiai T; Masuda T; Yagi M; Kasai R; Furuyama T; Tsukamoto K; Ito H; Igari K; Aihara A; Kumagai Y; Iida M; Odajima H; Tanaka S; Arii S; Yamazaki S
    Int Surg; 2012; 97(1):6-13. PubMed ID: 23101994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Three cases of resected pulmonary metastasis from colorectal cancer after preoperative chemotherapy].
    Imaizumi K; Koshiishi H; Nakata T; Matsuyama T; Hirano T; Okuno K; Yoshimura T; Ebana H; Ikeda N
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2056-8. PubMed ID: 25731421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Case of Unresectable Recurrent Colorectal Cancer with Regorafenib Treatment and Long-Term Survival].
    Maruo H; Sato S; Nakamura T; Sekimori K; Obayashi M; Hayashi Y; Ishimatsu H; Shoji T; Hirayama K; Yamazaki M
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):1670-1672. PubMed ID: 35046292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer].
    Kono T; Yokokawa H; Miyano Y; Oyama K; Yoshimatsu K; Koike T; Shiozawa S
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1278-1280. PubMed ID: 34657063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Patient with Cavitated Pulmonary Metastases Treated with Regorafenib].
    Taniguchi M; Mori M; Sata N; Fujii H
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):757-9. PubMed ID: 27306815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
    Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
    J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Case of Metastatic Lung Cancer from Colon Cancer with a Long Partial Response with Regorafenib Treatment].
    Iseki Y; Yashiro M; Shibutani M; Nagahara H; Maeda K; Matsutani S; Tamura T; Ohira G; Yamazoe S; Kimura K; Toyokawa T; Amano R; Tanaka H; Muguruma K; Hirakawa K; Ohira M
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2338-2340. PubMed ID: 28133314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effective chemotherapy with bevacizumab/FOLFOX4 for neuroendocrine carcinoma of the ascending colon - a case study].
    Tanabe H; Takase T; Morimoto D; Tanaka Y; Shibata A; Yaguchi T
    Gan To Kagaku Ryoho; 2014 May; 41(5):661-4. PubMed ID: 24917018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
    Kume S; Takahashi M; Kubota T; Hirata T; Torigoe Y; Ikeda O; Goto Y
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1809-12. PubMed ID: 20841953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Case of Synchronous Liver Metastasis of Ascending Colon Cancer with Pathological Complete Response to S-1/Oxaliplatin (SOX) and Bevacizumab].
    Tago T; Suzuki K; Nishida K; Maruyama T; Shimazaki J; Shimoda M; Suzuki S; Kou K; Morishita Y
    Gan To Kagaku Ryoho; 2018 May; 45(5):871-874. PubMed ID: 30026455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.